Overview of lipid metabolism and of the management of hypercholesterolemia
Generalidades del metabolismo de los lípidos y del manejo de la de los lípidos y del manejo de la hipercolesterolemia
Main Article Content
Abstract
Introduction: lipids are an important part of human biology and are precursors for the synthesis of steroid hormones and eicosanoid derivatives. Lipid requirements are satisfied through an endogenous pathway which consists of intracellular synthesis of lipids, and the intake and absorption of fats from food which constitutes the exogenous pathway. Being aware of these pathways is important for it is the starting point for achieving an adequate and timely therapeutic approach, but despite the availability of laboratory methodologies for their quantification and diagnosis, familial hypercholesterolemia (FH) remains underdiagnosed. Discussion: clinicians need to be aware of this important disorder for it is a major cause of premature cardiovascular events. Heterozygous FH has a prevalence of approximately 1/500 persons. Most FHs are secondary to impaired LDL receptor function, resulting from the presence of multiple mutations. which affects cholesterol processing. Conclusion: clinical manifestations are associated with increased LDL levels (greater than 190 mg/dL) and total cholesterol levels greater than 300 mg/dL present from birth. Statins are the first line drugs, but may not be sufficient. requiring add on therapies such as ezetimibe, bile acid sequestrants and PCSK9 inhibitors.
Keywords:
Downloads
Article Details
References
Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med. 2011;365(19):1812-23. doi: 10.1056/NEJMra1104901 DOI: https://doi.org/10.1056/NEJMra1104901
Michos ED, McEvoy JW, Blumenthal RS. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2019;381(16):1557-1567. doi: 10.1056/NEJMra1806939 DOI: https://doi.org/10.1056/NEJMra1806939
Ramasamy, I. Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med. 2014;52(12):1695-727. doi: 10.1515/cclm-2013-0358 DOI: https://doi.org/10.1515/cclm-2013-0358
Fouchier, S.W., Dallinga-Thie, G.M. Meijers, J.C. Kastelein, J.J.P, Defesche, J.C, Kathiresan, S. Hovingh, G.K. Mutations in stap1 are associated with autosomal dominant hypercholesterolemia. Atherosclerosis. 2014;235(2):e17-e18. https://doi.org/10.1016/j.atherosclerosis.2014.05.019 DOI: https://doi.org/10.1016/j.atherosclerosis.2014.05.019
Sirtori, CR. The Pharmacology of Statins. Pharmacol Res. 2014;88:3-11. doi: 10.1016/j.phrs.2014.03.002 DOI: https://doi.org/10.1016/j.phrs.2014.03.002
Fouchier S, Dallinga - Thie G, Meijersm J, Zelcer N, Kastelein J, Kees D. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res. 2014;115(6):552-5. doi: 10.1161/ CIRCRESAHA.115.304660 DOI: https://doi.org/10.1161/CIRCRESAHA.115.304660
Brunzell J, Chait A. Lipoprotein metabolism: structure and function. Encyclopedia of life sciences, 2002. DOI: https://doi.org/10.1038/npg.els.0000609
Brautbar A, Leary E. Rasmussen, K. Wilson, DP. Steiner, RD. Vilrani, S. Genetics of familiar hypercholesterolemia. Curr Atheroscler Rep. 2015;17(4):491. doi: 10.1007/s11883-015-0491-z DOI: https://doi.org/10.1007/s11883-015-0491-z
Shepherd, J. Lipoprotein metabolism: an overview. Drugs. 1994;47 Suppl 2:1-10. doi: 10.2165/00003495-199400472-00003 DOI: https://doi.org/10.2165/00003495-199400472-00003
Pullinger C, Kane J. Lipid Metabolism. In: Offermanns S, Rosenthal W, editors. Encyclopedia of Molecular Pharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2008. p. 691.
Shen WJ, Azhar S. SR-B1: A unique multifunctional receptor for cholesterol influx and efflux. Annu. Rev. Physiol. 2018;80:95-116. doi: 10.1146/annurev-physiol-021317-121550 DOI: https://doi.org/10.1146/annurev-physiol-021317-121550
Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol. 2019;16(1):9-20. doi: 10.1038/s41569-018-0052-6 DOI: https://doi.org/10.1038/s41569-018-0052-6
Ibrahim MA, Asuka E, Jialal I. Hypercholesterolemia [Internet]. 2019 [Updated 2020 Nov 26]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK459188/
14.Vogt, A. The genetic of familiar hypercholesterolemia and emerging therapies. Appl Clin Genet. 2015;8:27-36. doi: 10.2147/ TACG.S44315. eCollection 2015 DOI: https://doi.org/10.2147/TACG.S44315
Zanoni P, Velagapaundi S, Yalcinkaya M, Rohrer L, Von Eckardstein A. Endocytosis of lipoproteins Atherosclerosis. 2018;275:273-295. doi: 10.1016/j.atherosclerosis.2018.06.881 DOI: https://doi.org/10.1016/j.atherosclerosis.2018.06.881
Hegele R. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet. 2009;10(2):109-21. doi: 10.1038/ nrg2481 DOI: https://doi.org/10.1038/nrg2481
Gryn S, Hegele R. Doctor My Eyes: A Statin-Cataract Connection. Can J Cardiol. 2014;30(12):1508-10. doi: 10.1016/j.cjca.2014.08.019 DOI: https://doi.org/10.1016/j.cjca.2014.08.019
Beckett RD, Schepers SM, Gordon SK. Risk of new - onset diabetes associated with statin use. SAGE Open Med. 2015;3:2050312115605518. doi: 10.1177/2050312115605518 DOI: https://doi.org/10.1177/2050312115605518
Montero MC, Balosa R, Boxo JR. Statins in patients without cardiovascular disease: a critical review. FAP. 2012;10(2):36-43 DOI: https://doi.org/10.1016/S2172-3761(12)70056-0